好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Suboxone abuse with shared needle as a cause of Botulism in an IV drug user
Infectious Disease
P5 - Poster Session 5 (5:30 PM-6:30 PM)
4-027

To report a case of Botulism caused by shared IV needle use in an IV drug user. 

Botulism is a very rare but life threatening disease caused by the  Clostridium botulinum bacteria. It is mostly caused by ingestion of contaminated food and wound infection. The botulism toxin blocks the release of acetylcholine at the neuromuscular junction.

We chart reviewed a patient who presented with dysphagia, dysphonia, ptosis and cranial nerve deficits and was found to have Botulism.

A 30 year old male with history of type 1 diabetes mellitus presented with a two day history of dysphagia, dysarthria, ptosis, facial weakness, and ophthalmoparesis. On initial presentation he did not relate any risk factors for botulism exposure. His MRI brain was unremarkable. EMG demonstrated about 100% motor amplitude increment with 10 second exercise test consistent with a presynaptic neuromuscular junction abnormality and without any other features to suggest a Guillain Barre variant.He then admitted to use of his brother’s old  IV needle that had dried blood on it for recreational drug use 2 days prior to the onset of symptoms.  We diagnosed him with acute botulism and notified CDC. He received botulism anti-toxin and was started on Penicillin G. He stabilized clinically.

Botulism is a very rare and potentially fatal disease mostly caused by ingestion of contaminated food and wound infections. However with the opioid epidemic and increased IV drug abuse with possible contamination of injected substances, it is important to consider Botulism in this patient cohort. Prompt diagnosis is important for effective treatment. 

Authors/Disclosures
Shuvro Roy, MD (University of Washington)
PRESENTER
Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Roy has received research support from The Siegel Rare Neuroimmune Association.
Yasmeen Rauf, MBBS (UNC chapel hill) Dr. Rauf has nothing to disclose.
Chad Hoyle, MD (Ohio State University) Dr. Hoyle has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for National Football League. Dr. Hoyle has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avexis. Dr. Hoyle has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Reata. The institution of Dr. Hoyle has received research support from REATA. The institution of Dr. Hoyle has received research support from TAKEDA.